Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sensipar patient brochure misleading, US FDA tells Amgen

This article was originally published in Scrip

Executive Summary

A patient brochure forAmgen's hyperparathyroidism drug Sensipar (cinacalcet) is false and misleading because it omits and minimises risks and broadens the medicine's indication, the US FDAsaid. The brochure omits the serious risk of adynamic bone disease and the need for monitoring of hepatically impaired patients. The presentation of side- effects information minimises the severity, frequency and duration of nausea and vomiting. The promotion also misleadingly suggests Sensipar is indicated for all patients on dialysis, rather than just those who require treatment for secondary hyperparathyroidism with chronic kidney disease. Amgen said it was working with the FDA to address its concerns and has stopped distributing the brochure.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030781

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel